Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Amlodipine/Valsartan [Design Issues]

posted by Bebac user – Egypt, 2023-09-09 08:34 (1010 d 11:57 ago) – Posting: # 23713
Views: 7,413

The combination of Amlodipine and valsartan was published as two periods crossover but after checking the variability of Valsartan, it had more than 30%. Therefore, should I in those cases design this study as replicated or un-replicated ?

Complete thread:

Amlodipine/ValsartanBebac user 2023-09-09 06:34 [Design Issues]
- Amlodipine/Valsartan Helmut 2023-09-12 06:48
  - Amlodipine/Valsartan Kumarnaidu2 2023-12-06 09:36
    - Amlodipine/Valsartan dshah 2023-12-06 16:49
      - Amlodipine/Valsartan Kumarnaidu2 2023-12-07 02:42
    - Use all data and avoid the partial replicate design for the FDA Helmut 2023-12-07 09:01

Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
103 visitors (0 registered, 103 guests [including 10 identified bots]).
Forum time: 20:31 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another. Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz